Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Study Objectives: To assess long-term efficacy and safety of lemborexant (LEM), a novel dual orexin receptor antagonist, versus placebo in adults with insomnia disorder. Methods: This was a 12-month, global, multicenter, randomized, double-blind, parallel-group phase 3 study comprising a 6-month placebo-controlled period (reported here) followed by a 6-month active-treatment-only period (reported separately). A total of 949 participants with insomnia (age ≥18 years) were randomized, received treatment with an oral dose of placebo or LEM (5 mg [LEM5] or 10 mg [LEM10]) and were analyzed. Sleep onset and sleep maintenance endpoints were analyzed from daily electronic sleep diary data. Treatment-emergent adverse events (TEAEs) were monitored throughout the study. Results: Decreases from baseline in patient-reported (subjective) sleep onset latency and subjective wake after sleep onset, and increases from baseline in subjective sleep efficiency, were significantly greater with LEM5 and LEM10 versus placebo. Significant benefits over placebo were observed at the end of month 6, and at most time points assessed over the 6-month period, indicating long-term sustained efficacy of LEM. A significantly greater percentage of sleep onset responders and sleep maintenance responders were observed with LEM treatment versus placebo. Participants treated with LEM reported a significant improvement in quality of sleep after 6 months versus placebo. The majority of TEAEs were mild or moderate. There was a low rate of serious TEAEs and no deaths. Conclusions: LEM5 and LEM10 provided significant benefit on sleep onset and sleep maintenance in individuals with insomnia disorder versus placebo, and was well tolerated. Clinical trial registration: ClinicalTrials.gov, NCT02952820; ClinicalTrialsRegister.eu, EudraCT Number 2015-001463-39
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 2×
“Participants were required to score ≥15 on the Insomnia Severity Index (ISI) [31].”
MethodInfluentialSTOP Questionnaire: A Tool to Screen Patients for Obstructive Sleep Apnea
Chung, F., Yegneswaran, B., Liao, P., Chung, S. A., Vairavanathan, S., Islam, S., Khajehdehi, A., & Shapiro, C. M. (2008) · Anesthesiology · doi:10.1097/aln.0b013e31816d83e4 · Cited by 2,355 · cited 3×
“A sleep disorders screening battery was conducted, which consisted of the STOPBang [32], International Restless Legs Scale (IRLS) [33], and the Epworth Sleepiness Scale (ESS) [34] to screen for potential undiagnosed obstructive sleep apnea, restless legs syndrome, and excessive daytime sleepiness, respectively.”
MethodReliability and Factor Analysis of the Epworth Sleepiness Scale
Johns, M. W. (1992) · Sleep · doi:10.1093/sleep/15.4.376 · Cited by 2,122 · cited 3×
“A sleep disorders screening battery was conducted, which consisted of the STOPBang [32], International Restless Legs Scale (IRLS) [33], and the Epworth Sleepiness Scale (ESS) [34] to screen for potential undiagnosed obstructive sleep apnea, restless legs syndrome, and excessive daytime sleepiness, respectively.”
MethodClinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943 · cited 1×
“This threshold has clinical importance, as the American Academy of Sleep Medicine guidelines indicate that achieving a sleep efficiency >80% to 85% is an important goal of insomnia treatment [35].”
BackgroundSateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519 · cited 3×
“Current pharmacologic options for insomnia include γ-aminobutyric acid type-A receptor agonists, such as sedative-hypnotic benzodiazepines and nonbenzodiazepine Z-drugs, melatonin receptor agonists, sedating antidepressants, sedating antihistamines, and dual orexin receptor antagonists [3].”
BackgroundInfluentialKrystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630
Michelson, D., Snyder, E., Paradis, E., Chengan-Liu, M., Snavely, D. B., Hutzelmann, J., Walsh, J. K., Krystal, A. D., Benca, R. M., Cohn, M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70053-5 · Cited by 519 · cited 1×
“However, some long-term studies used intermittent dosing [10, 11] or doses higher than what has been approved [12, 13].”
BackgroundRosenberg, R., Murphy, P., Zammit, G., Mayleben, D., Kumar, D., Dhadda, S., Filippov, G., LoPresti, A., & Moline, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18254 · Cited by 412 · cited 3×
“In the 1-month pivotal phase 3 study for insomnia disorder, SUNRISE 1 (NCT02783729; E2006-G000-304), LEM, administered orally at doses of 5 or 10 mg, provided significant benefit on objective measures of sleep onset and sleep maintenance compared with placebo and zolpidem tartrate extended release in adults with insom…”
BackgroundResultSelf-citationMurphy, P., Moline, M., Mayleben, D., Rosenberg, R., Zammit, G., Pinner, K., Dhadda, S., Hong, Q., Giorgi, L., & Satlin, A. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6800 · Cited by 329 · cited 2×
“These observations strengthen previous findings from studies of 15-night [27] and 1-month [26] durations, indicating that early benefits of LEM on sleep onset and sleep maintenance parameters are sustained long term.”
MethodResultSelf-citationOrexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant
Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., Lines, C., Roth, T., & Michelson, D. (2012) · Neurology · doi:10.1212/wnl.0b013e31827688ee · Cited by 322
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
Herring, W. J., Connor, K. M., Ivgy-May, N., Snyder, E., Liu, K., Snavely, D. B., Krystal, A. D., Walsh, J. K., Benca, R. M., Rosenberg, R., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.10.003 · Cited by 300
Walsh, J. K., Krystal, A. D., Amato, D. A., Rubens, R., Caron, J., Wessel, T. C., Schaefer, K., Roach, J., Wallenstein, G., & Roth, T. (2007) · Sleep · doi:10.1093/sleep/30.8.959 · Cited by 239
ROTH, T., WALSH, J., KRYSTAL, A., WESSEL, T., & ROEHRS, T. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.06.004 · Cited by 230
Vermeeren, A., Jongen, S., Murphy, P., Moline, M., Filippov, G., Pinner, K., Perdomo, C., Landry, I., Majid, O., Van Oers, A. C. M., et al. (2019) · Sleep · doi:10.1093/sleep/zsy260 · Cited by 228 · cited 2×
“In addition, LEM did not impair morning driving ability in healthy adult volunteers following bedtime dosing [28].”
BackgroundSelf-citationA multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia.
Scharf, M. B., Roth, T. G., Vogel, G. W., & Walsh, J. K. (1994) · PubMed · Cited by 223
Krystal, A. D., Erman, M., Zammit, G. K., Soubrane, C., & Roth, T. (2008) · Sleep · doi:10.1093/sleep/31.1.79 · Cited by 212
Self-citationThe Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
Wang, C., Wang, Q., Ji, B., Pan, Y., Xu, C., Cheng, B., Bai, B., & Chen, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00220 · Cited by 207 · cited 1×
“Orexin neuropeptides bind orexin receptor types 1 and 2 and regulate several physiologic processes, including feeding behavior, arousal, and the sleepwake cycle [23].”
BackgroundElie, R., Ruther, E., Farr, I., Emilien, G., Salinas, E., & The Zaleplon Clinical Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0806 · Cited by 191
Mayer, G., Wang-Weigand, G., Roth‐Schechter, B. F., Lehmann, R., Staner, C., & Partinen, M. (2009) · SLEEP · doi:10.1093/sleep/32.3.351 · Cited by 145
Long-Term, Non-Nightly Administration of Zolpidem in the Treatment of Patients With Primary Insomnia
Perlis, M. L., McCall, W. V., Krystal, A. D., & Walsh, J. K. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0816 · Cited by 144
Ancoli-Israel, S., Walsh, J. K., Mangano, R. M., & Fujimori, M. (1999) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v01n0404 · Cited by 140
Wickwire, E. M., Tom, S. E., Scharf, S. M., Vadlamani, A., Bulatao, I. G., & Albrecht, J. S. (2019) · Sleep · doi:10.1093/sleep/zsz007 · Cited by 139 · cited 1×
“Insomnia is a common sleep-wake disorder that is associated with substantial functional impairment and increased health care utilization [1, 2].”
BackgroundAbetz, L. N., Arbuckle, R. A., Allen, R. P., García-Borreguero, D., Hening, W. A., Walters, A. S., Mavraki, E., & Kirsch, J. M. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2005.12.011 · Cited by 126 · cited 3×
“A sleep disorders screening battery was conducted, which consisted of the STOPBang [32], International Restless Legs Scale (IRLS) [33], and the Epworth Sleepiness Scale (ESS) [34] to screen for potential undiagnosed obstructive sleep apnea, restless legs syndrome, and excessive daytime sleepiness, respectively.”
MethodBeuckmann, C. T., Suzuki, M., Ueno, T., Nagaoka, K., Arai, T., & Higashiyama, H. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241422 · Cited by 123 · cited 2×
“Lemborexant (LEM) is a dual orexin receptor antagonist [24] recently approved in the United States and Japan for the treatment of adult and elderly persons with insomnia [25].”
BackgroundAncoli-lsrael, S., Krystal, A. D., McCall, W. V., Schaefer, K., Wilson, A., Claus, R., Rubens, R., & Roth, T. (2010) · Sleep · doi:10.1093/sleep/33.2.225 · Cited by 96
Zaleplon improves sleep without producing rebound effects in outpatients with insomnia
Fry, J., Scharf, M., Mangano, R., & Fujimori, M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00003 · Cited by 93
Efficacy of Eight Months of Nightly Zolpidem: A Prospective Placebo-Controlled Study
Randall, S., Roehrs, T. A., & Roth, T. (2012) · Sleep · doi:10.5665/sleep.2208 · Cited by 92 · cited 1×
“However, some long-term studies used intermittent dosing [10, 11] or doses higher than what has been approved [12, 13].”
BackgroundMurphy, P., Kumar, D., Zammit, G. K., Rosenberg, R. P., & Moline, M. L. (2020) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.8294 · Cited by 82
Self-citationOrexin receptor antagonists as therapeutic agents for insomnia
Equihua-Benítez, A. C., la Herrán-Arita, A. K. D., & Drucker-Colín, R. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00163 · Cited by 71 · cited 1×
“The orexin/hypocretin system has been established as a target for insomnia treatment [22].”
BackgroundRoehrs, T. A., Randall, S., Harris, E., Maan, R., & Roth, T. (2011) · Sleep · doi:10.1093/sleep/34.2.207 · Cited by 42
Healthcare utilization and costs in persons with insomnia in a managed care population.
Anderson, L. H., Whitebird, R. R., Schultz, J., McEvoy, C., Kreitzer, M. J., & Gross, C. R. (2014) · PubMed · Cited by 37
Long-term, Non-nightly Administration of Zolpidem in the Treatment of Patients With Primary Insomnia
Ballenger, J. (2006) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70258-5 · Cited by 21
Uchimura, N., Kamijo, A., & Takase, T. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-15 · Cited by 20
Cited by
Zhou, M., Tang, J., Li, S., Li, Y., & Zhao, M. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.1029554 · Cited by 24
2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association
Drager, L. F., Assis, M., Bacelar, A. F. R., Poyares, D. L. R., Conway, S. G., Pires, G. N., de Azevedo, A. P., Carissimi, A., Eckeli, A. L., Pentagna, Á., et al. (2023) · Sleep Science · doi:10.1055/s-0043-1776281 · Cited by 25
“Ramelteon has also been associated with improving persistent sleep latency (time from lights off to the fi rst sleep lasting at least 10minutes), improving sleep ef fi ciency, and objective TST. Drug interactions, contraindications, and side effects: When co-administered with ramelteon, fl uvoxamine…”
BackgroundOzone, M., Hirota, S., Ariyoshi, Y., Hayashida, K., Ikegami, A., Habukawa, M., Ohshima, H., Harada, D., Hiejima, H., Kotorii, N., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02811-2 · Cited by 24
Metadata
- Authors
- Kärppä, M., Yardley, J., Pinner, K., Filippov, G., Zammit, G., Moline, M., Perdomo, C., Inoue, Y., Ishikawa, K., & Kubota, N.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-06-26
- Volume
- 43
- Issue
- 9
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W3037971062
- Cited by
- 177
- References
- 35
- FWCI
- 20.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.